Niels Lindner

USPTO Granted Patents = 29 (Patent Applications = 18)

EPO Patents = 20 (Patent Applications = 34)

Average Co-Inventor Count = 11.5

ph-index = 7

Forward Citations = 125(Granted Patents)

Company Filing History:

20 out of 378

Bayer Pharma Aktiengesellschaft

patents

6 out of 721

Bayer Intellectual Property Gmbh

patents

5 out of 12,157

Bayer Aktiengesellschaft

patents

4. 4 out of 54

Bayer Animal Health Gmbh

where one patent can have more than one assignee

Years Active: 2014-2024

Loading Chart...

29 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12180227 - Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders (2024-12-31),

2. 11572357 - Quinoline derivatives (2023-02-07),

3. 11505545 - Anthelmintic quinoline-3-carboxamide derivatives (2022-11-22),

4. 11208400 - Substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof (2021-12-28),

5. 11173151 - Substituted triazole derivatives and uses thereof (2021-11-16),

6. 11098063 - Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders (2021-08-24),

7. 10889573 - Anthelmintic quinoline-3-carboxamide derivatives (2021-01-12),

8. 10722501 - Substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-A]pyridine-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-C][1,2,4]triazol-3-ones, and use thereof (2020-07-28),

9. 10662185 - Amino-substituted imidazo[1,2-A] pyridinecarboxamides and their use (2020-05-26),

10. 10273226 - Pyrazolyl-heteroarylamides as pesticides (2019-04-30),

11. 10052312 - Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use (2018-08-21),

12. 10047096 - Substituted pyridobenzodiazepinone-derivatives and use thereof (2018-08-14),

13. 9776997 - 3-aryl-substituted imidazo[1,2-A]pyridines and their use (2017-10-03),

14. 9771360 - Cyano-substituted imidazo[1,2-A]pyridinecarboxamides and their use (2017-09-26),

15. 9624214 - Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use (2017-04-18),

Title: Niels Lindner: Innovator in Pharmaceutical Chemistry

Introduction: Niels Lindner, based in Wuppertal, Germany, is a prominent inventor known for his significant contributions to pharmaceutical chemistry. With an impressive portfolio of 29 patents, Lindner's work focuses on innovative compounds aimed at treating various diseases, particularly breathing disorders.

Latest Patents: Among his latest patents, Niels Lindner has developed novel diazabicyclic substituted imidazopyrimidines. These compounds are designed for the treatment of breathing disorders, including sleep-related issues such as obstructive and central sleep apnea, and snoring. His patent describes methods for producing these compounds and their use in preparing medicaments for the prevention and treatment of diseases. Additionally, he has created a patent for new quinoline derivatives, which include methods of preparation, intermediate compounds, and pharmaceutical compositions targeting helminth infections.

Career Highlights: Niels Lindner has held positions at Bayer Pharma AG and Bayer Intellectual Property GmbH. His work in these organizations has allowed him to develop a strong foundation in pharmaceutical innovation, contributing to advancements in drug development and formulation.

Collaborations: Throughout his career, Lindner has collaborated with notable colleagues, including Johannes-Peter Stasch and Frank Wunder. These partnerships have facilitated the exchange of ideas and fostered creativity within the industry, leading to groundbreaking innovations in medical treatments.

Conclusion: Niels Lindner stands out as a prolific inventor whose work in developing innovative pharmaceutical compounds reflects his commitment to improving health outcomes. With a solid track record of patents and collaborations, he continues to make a significant impact in the field of chemistry and medicine.

This text is generated by artificial intelligence and may not be accurate.